Company intelligence / Profile preview

Innoprot

Derio, Biscay/Bizkaia, Spain

Ownership: Private
Development stage: Other

Overview

Innoprot provides advanced cell-based assay platforms for multiplexed GPCR, receptor, and enzyme screenings, aiding preclinical drug discovery, particularly for neurodegenerative diseases and fibrosis.

Therapeutic areas: NeurologyOther
Modalities: Cell-based assay technologyRecombinant proteinRecombinant cell lineSmall molecule (screening-focused)Biologic (screening-focused)Peptides (screening-focused)
Industry: Drug Discovery Services

Partnerships

BiocatNextGen Microfluidics Consortium

Beyond the preview

Go deeper on Innoprot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoprot.

Explore the full profile